2FVJ

A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG) recruits pparg-coactivator-1 alpha (PGC1A) but potentiates insulin signaling in vitro

Summary for 2FVJ

• Entry DOI: 10.2210/pdb2fvj/pdb
• Descriptor: Peroxisome proliferator-activated receptor gamma, Nuclear receptor coactivator 1, 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXY-4-{[4-(2-METHOXYPHENYL)PIPERIDIN-1-YL]METHYL}ISOQUINOLINE, ... (5 entities in total)
• Functional Keywords: nuclear receptor lbd, alpha helical sandwich, signaling protein
• Biological source: Homo sapiens (human); More
• Cellular location: Nucleus: P37231; Nucleus (By similarity): Q15788
• Total number of polymer chains: 2
• Total formula weight: 33103.48

Authors

Benz, J.,Burgermeister, E.,Flament, A.,Schnoebelen, A.,Stihle, M.,Gsell, B.,Rufer, A.,Ruf, A.,Kuhn, B.,Maerki, H.P.,Mizrahi, J.,Sebokova, E.,Niesor, E.,Meyer, M. (deposition date: 2006-01-31, release date: 2006-05-16, Last modification date: 2024-04-03)

Primary citation

Burgermeister, E.,Schnoebelen, A.,Flament, A.,Benz, J.,Stihle, M.,Gsell, B.,Rufer, A.,Ruf, A.,Kuhn, B.,Maerki, H.P.,Mizrahi, J.,Sebokova, E.,Niesor, E.,Meyer, M.
A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro
Mol.Endocrinol., 20:809-830, 2006

PubMed Abstract: Partial agonists of peroxisome proliferator-activated receptor-gamma (PPARgamma), also termed selective PPARgamma modulators, are expected to uncouple insulin sensitization from triglyceride (TG) storage in patients with type 2 diabetes mellitus. These agents shall thus avoid adverse effects, such as body weight gain, exerted by full agonists such as thiazolidinediones. In this context, we describe the identification and characterization of the isoquinoline derivative PA-082, a prototype of a novel class of non-thiazolidinedione partial PPARgamma ligands. In a cocrystal with PPARgamma it was bound within the ligand-binding pocket without direct contact to helix 12. The compound displayed partial agonism in biochemical and cell-based transactivation assays and caused preferential recruitment of PPARgamma-coactivator-1alpha (PGC1alpha) to the receptor, a feature shared with other selective PPARgamma modulators. It antagonized rosiglitazone-driven transactivation and TG accumulation during de novo adipogenic differentiation of murine C3H10T1/2 mesenchymal stem cells. The latter effect was mimicked by overexpression of wild-type PGC1alpha but not its LXXLL-deficient mutant. Despite failing to promote TG loading, PA-082 induced mRNAs of genes encoding components of insulin signaling and adipogenic differentiation pathways. It potentiated glucose uptake and inhibited the negative cross-talk of TNFalpha on protein kinase B (AKT) phosphorylation in mature adipocytes and HepG2 human hepatoma cells. PGC1alpha is a key regulator of energy expenditure and down-regulated in diabetics. We thus propose that selective recruitment of PGC1alpha to favorable PPARgamma-target genes provides a possible molecular mechanism whereby partial PPARgamma agonists dissociate TG accumulation from insulin signaling.

PubMed: 16373399
DOI: 10.1210/me.2005-0171

Experimental method

X-RAY DIFFRACTION (1.99 Å)